CP Antibody
Description
Definition and Biochemical Basis
CCP antibodies, also termed anti-citrullinated protein antibodies (ACPAs), target proteins where arginine residues are enzymatically converted to citrulline by peptidylarginine deiminases (PADs) during inflammation . This process occurs in synovial tissues, triggering an autoimmune response in RA . CCP antibodies are detected via immunoassays using cyclic citrullinated peptides, which mimic endogenous citrullinated antigens like vimentin and fibrinogen .
Clinical Significance in Rheumatoid Arthritis Diagnosis
CCP antibodies are pivotal in distinguishing RA from other arthritides due to their specificity. Key points include:
-
Prevalence: Detected in 66–74% of RA patients , with higher sensitivity in seropositive RA (e.g., RF+ patients) .
-
Diagnostic Utility:
-
ACR/EULAR 2010 Criteria: ACPA testing (via CCP assays) is included in updated RA classification criteria .
Sensitivity and Specificity: Comparative Analysis
Studies report variability in sensitivity and specificity due to differing thresholds and populations. Below is a synthesis of key findings:
Key Observations:
-
Specificity remains consistently high (90–100%), while sensitivity varies due to methodological differences .
-
Lower thresholds (e.g., 20 UI/ml vs. higher cutoffs) improve sensitivity but may slightly reduce specificity .
Research Findings on Disease Activity and Prognosis
CCP antibodies correlate with RA severity and predictive outcomes:
-
Disease Activity:
-
Prognosis:
Methodology and Interpretation of Testing
CCP antibody detection employs enzyme-linked immunosorbent assays (ELISAs):
Clinical Implications and Guidelines
-
Diagnostic Workup:
-
Therapeutic Monitoring:
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Ceruloplasmin has been identified as a biomarker for chronic kidney disease in the urine of sickle cell disease patients. PMID: 29127684
- Maternal blood ceruloplasmin levels were found to be lower in pregnancies affected by neural tube defects compared to healthy controls. PMID: 28397206
- Increased serum transferrin and ceruloplasmin turnover have been reported in diet-controlled patients with type 2 diabetes. PMID: 29079528
- Strong correlations between meconium concentrations of ceruloplasmin, lactoferrin, and myeloperoxidase suggest a potential role for these proteins in maintaining homeostasis within the intrauterine fetal environment. Measuring these proteins in meconium may serve as biomarkers for assessing oxidative balance impairment during intrauterine life, with potential implications for disease development in adulthood. PMID: 27903408
- A woman in her 50s presenting with movement disorder was diagnosed with aceruloplasminemia, a rare autosomal recessive disorder characterized by iron accumulation in major organs. Genetic testing confirmed mutations in the ceruloplasmin gene (c.1864 + 1G>C). PMID: 27416276
- Higher circulating ceruloplasmin levels have been linked to an increased risk of atrial fibrillation. PMID: 28427851
- In cases of ATP7B mutations, the more severe the impact on ATP7B protein, the younger the onset age and the lower the ceruloplasmin level. This study highlights the feasibility of presymptomatic DNA diagnosis and the ability to predict clinical manifestations or severity of Wilson disease (WD) based on identified mutations and genotype-phenotype correlation. PMID: 27982432
- Ceruloplasmin is believed to be associated with advanced T stage and perineural invasion, potentially serving as a prognostic marker for bile duct cancer. PMID: 28423673
- Mechanistically, ceruloplasmin can specifically interact with the hepatitis B virus middle surface protein. PMID: 28678687
- Research has shown that levels of antioxidant response element (ARE), ceruloplasmin (CLP), catalase (CAT), and myeloperoxidase (MPO) differ between pediatric patients with sepsis and healthy controls. ARE levels may be a potent biomarker for sepsis in critically ill patients in intensive care units. PMID: 28167245
- Ceruloplasmin has been found to be independently and negatively associated with liver fibrosis in chronic hepatitis B. PMID: 27920479
- Coronary atherosclerosis is characterized by serum C4 complement up-regulation and ceruloplasmin down-regulation. PMID: 28091899
- Data indicates that the concentration of ceruloplasmin (ferroxidase; Cp) was significantly higher in the low hemoglobin (Hb) subsample compared to the high Hb subsample. PMID: 27235174
- Serum ceruloplasmin levels were lower in the primary open-angle glaucoma group compared to the group with only cataracts. PMID: 27109647
- Measuring serum ceruloplasmin levels in adolescents could be a useful tool for identifying patients at a higher risk of future cardiovascular disease. PMID: 27083758
- A key finding of this study is that ceruloplasmin specific activity is associated with a decreased risk of developing Alzheimer's disease. PMID: 26836154
- The pathological cerebrospinal fluid environment in Parkinson's disease patients promoted similar modifications in exogenously added ceruloplasmin. PMID: 26537957
- Homozygosity for c.1948G>A has been described in a Dutch family with aceruloplasminemia. PMID: 25661792
- Ceruloplasmin-mediated neuroprotection occurs through the inhibition of seizure-associated oxidative damage. PMID: 25843655
- Studies have investigated paraoxonase-1 (PON-1) and ferroxidase activities in older patients with mild cognitive impairment, late-onset Alzheimer's disease, or vascular dementia. PMID: 25490030
- Research suggests that common genetic variants of the ceruloplasmin gene are associated with Parkinson's disease, and further investigation is needed to explore their role in the disease. PMID: 25758665
- Through bioinformatic screening, ceruloplasmin has been identified as a novel adipokine with increased expression in adipose tissue of obese subjects as well as in cells from obesity-associated cancers. PMID: 24676332
- The sLe(x)/CP ratio tended to be higher for pancreatic adenocarcinoma. PMID: 25595436
- Brain microvascular endothelial cell-secreted cytokine activity increases the gene expression of neighboring C6 glioma CP, which reciprocally acts on basolateral BMVEC ferroportin to enhance brain iron import. PMID: 25311416
- High ceruloplasmin levels are associated with preeclampsia. PMID: 25463281
- Mercury metallation of the bacterial copper protein azurin is analogous to that of human ceruloplasmin and factor VIII in mercury poisoning. PMID: 25265377
- Reduced serum FeOx activity, which can potentially lead to an increase in oxidative stress-induced biomolecular damage, appears to be a shared condition in inflammatory disorders of the central nervous system, including multiple sclerosis (MS). PMID: 25398823
- This review describes the primary role of ceruloplasmin in iron turnover, which is the oxidation of Fe2+ to Fe3+. This process is crucial for iron binding to transferrin (the primary iron-transporting protein), as well as to ferritin (the main iron-storage protein). PMID: 24988611
- Ceruloplasmin and hepcidin differentially regulate iron efflux from brain microvascular endothelial cells. PMID: 24533165
- The core-fucosylation ratio of ceruloplasmin increases significantly in alcohol-related hepatocellular carcinoma. PMID: 24799124
- In chronic kidney disease (CKD) patients, increased serum ceruloplasmin (a regulator of nitric oxide activity) is associated with an increased risk of long-term adverse cardiovascular events, even after adjusting for traditional clinical/biological risk factors. PMID: 24311705
- Ceruloplasmin and gelsolin are closely associated with the oncogene NF-kappab. PMID: 23925487
- Increased urinary excretion of plasma proteins, such as IgG, ceruloplasmin, and transferrin (with varying molecular radii of 55 A or less and different isoelectric points), precedes the development of microalbuminuria in patients with non-insulin-dependent diabetes mellitus (NIDDM) and hypertension. PMID: 24256706
- The main result of this meta-analysis is that copper not bound to ceruloplasmin appears significantly increased in subjects with Alzheimer's disease compared to healthy controls. PMID: 24072069
- Ceruloplasmin levels correlate negatively and indirectly with inflammation and fibrosis stages in male chronic hepatitis B patients. PMID: 24282481
- Both ceruloplasmin NGR sites can deamidate during aging under oxidative conditions, likely due to oxidative-induced structural changes, promoting a gain of function in integrin binding, signaling, and cell adhesion. PMID: 24366863
- Findings indicate a causal role for ceruloplasmin in atrial fibrillation (AF) pathophysiology, suggesting that ceruloplasmin may be a mediator in a specific inflammatory pathway that causally links inflammatory diseases and AF incidence. PMID: 24118451
- A novel homozygous mutation of c.2185 delC in exon 12 was identified in the ceruloplasmin gene in a patient with aceruloplasminemia. PMID: 23812204
- Eosinophil activation occurred in early and late responses after L-ASA nasal provocation testing (NPT) in the upper airway mucosa of aspirin-exacerbated respiratory disease (AERD) patients, where apolipoprotein A1 (ApoA1), alpha-2-macroglobulin (alpha2M), and ceruloplasmin (CP), as well as cysteinyl leukotrienes (CysLT), may be involved in eosinophilic inflammation. PMID: 23786280
- The diffusion of an Fe(2+) ion from the inner opening of the human H-chain ferritin to a ferroxidase site located in the interior region of the protein coat is assisted by Thr135, His136, and Tyr137. PMID: 23344859
- Ceruloplasmin was significantly elevated in patients with ischemic or nonischemic cardiomyopathy and showed a linear correlation with C-reactive protein and left ventricular ejection fraction (LVEF). PMID: 23781119
- Ceruloplasmin (Cp) was associated with incident heart failure, mortality, and cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) population. PMID: 23861484
- Data suggests that serum ceruloplasmin (CP) levels decrease according to the severity of pediatric nonalcoholic fatty liver disease (NAFLD); therefore, serum CP may serve as a biomarker to differentiate children with severe NAFLD. PMID: 23154483
- Plasma ceruloplasmin is a potential plasma biomarker for acute graft-versus-host disease (aGvHD), and it also holds prognostic value for risk-adapted prophylaxis. PMID: 23505556
- Iron efflux from human brain microvasculature endothelial cells ferroportin requires the action of an exocytoplasmic ferroxidase, which can be either endogenous hephaestin or extracellular ceruloplasmin. PMID: 23640881
- A study examining the effects of occupational exposure to lead among metallurgy workers in Poland on blood levels of transferrin (TRF), ceruloplasmin (CER), and haptoglobin (HPG) showed that blood levels of copper and CER were elevated with lead exposure. PMID: 22923205
- Ceruloplasmin is expected to provide a protective shield against inadvertent oxidant production by myeloperoxidase during inflammation. PMID: 23306200
- Letter: reports mutations in the ceruloplasmin promoter and their potential role in iron homeostasis in patients with porphyria cutanea tarda. PMID: 23012398
- Study to determine if genetic variations identified in the CP gene contribute to esophageal cancer (OC) pathogenesis or susceptibility in the Black Xhosa-speaking South African population; statistically significant associations were found for two of the novel variants with OC in this study, and they could potentially contribute to disease susceptibility. PMID: 21901748
- Changes in the levels of three acute phase proteins: ceruloplasmin, alpha1-antitrypsin, and orosomucoid in oral fluid and blood plasma were examined in patients with periodontitis and myocardial infarction. PMID: 22708402
Q&A
What is the biological basis for anti-CCP antibody formation in rheumatoid arthritis?
Anti-CCP antibodies target citrullinated peptides, which are formed through post-translational modification of arginine residues. This process, called citrullination or deimination, is catalyzed by peptidylarginine deiminases (PAD) and involves the hydrolysis of the positively charged NH₂ group of arginine to a neutral oxygen group. In the inflamed synovium of RA patients, PAD2 and PAD4 isotypes are released from monocytes and macrophages into the extracellular space, where they citrullinate various proteins (vimentin, fibrin, fibrinogen, fibronectin, and keratin) . It is this oxygen group of peptidylcitrulline that becomes specifically recognized by autoantibodies in RA patients .
How do the diagnostic properties of anti-CCP antibodies compare to rheumatoid factor?
Anti-CCP antibodies demonstrate significantly higher specificity for RA compared to rheumatoid factor (RF), while maintaining comparable sensitivity:
| Parameter | Anti-CCP | Rheumatoid Factor (RF) |
|---|---|---|
| Sensitivity | 56-74% | Similar to anti-CCP |
| Specificity | 90-99% | Lower than anti-CCP |
| Present in early disease | Yes, even in preclinical phase | Less consistent |
| Prognostic value | High - predicts erosive disease | Moderate |
Anti-CCP antibodies are present in approximately 66-74% of RA patients with specificities of 96-99% . These autoantibodies may appear during the preclinical phase of the disease and can predict future RA development and radiographic joint destruction . Unlike RF, anti-CCP antibodies are rarely found in other rheumatic conditions, making them particularly valuable for differential diagnosis .
What are the standard methodologies for anti-CCP antibody detection?
The primary methodology for anti-CCP antibody detection is Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA) . The procedure involves:
-
Collection of serum in serum separator tubes (SST)
-
Separation of serum from cells within 2 hours of collection
-
Transfer of 1.0 mL serum to a standard transport tube (minimum 0.5 mL)
-
Storage conditions: ambient (48 hours), refrigerated (2 weeks), or frozen (30 days)
-
Analysis using ELISA with standardized controls and conjugates
Most clinical laboratories use second-generation (CCP2) or third-generation (CCP3) assays. CCP3 assays incorporate additional epitopes not present in the CCP2 antigen sequence, although most studies show no significant improvement of CCP3 compared to CCP2 assays .
How should researchers interpret quantitative anti-CCP test results?
Anti-CCP test results are typically reported in enzyme units per milliliter (EU/ml) and interpreted according to the following standardized ranges:
| Anti-CCP Test Result (EU/ml) | Interpretation | Clinical Significance |
|---|---|---|
| Less than 20 | Negative | Normal result, low probability of RA |
| 20-39 | Weakly Positive | Suggests possible RA, monitoring recommended |
| 40-59 | Moderately Positive | Higher probability of RA |
| More than 60 | Strongly Positive | High probability of RA with potential for more severe disease course |
Patients with weak positive results should be monitored and testing repeated . Higher titers of anti-CCP antibodies are associated with more severe, erosive disease and may indicate the need for more aggressive treatment .
What factors can affect the sensitivity and specificity of anti-CCP testing in research contexts?
Several factors can influence the diagnostic performance of anti-CCP testing:
-
Disease duration: Studies including early RA patients (disease duration <2 years) generally show lower sensitivity (higher miss-diagnosis rates over 40%) compared to studies with established RA patients (disease duration >2 years), which typically have miss-diagnosis rates of approximately 20% .
-
Assay generation: Second-generation (CCP2) and third-generation (CCP3) assays may yield different results, though most studies show no significant improvement with CCP3 .
-
Cut-off values: The threshold value for positivity is not internationally standardized, which can affect sensitivity measurements across studies .
-
Sample quality: Contaminated, heat-inactivated, grossly hemolyzed, icteric, or lipemic specimens may affect test results .
-
Population characteristics: Genetic factors can influence citrullination processes and may affect test performance in different populations .
How does the combined testing of anti-CCP and RF enhance diagnostic accuracy in research studies?
Combined testing strategies significantly improve diagnostic accuracy in RA research:
-
Both antibodies positive ("anti-CCP AND RF"): The pooled specificity reaches 96% (range 89-100%) with a sensitivity of 57% (range 33-80%). The positive likelihood ratio (LR) increases markedly from 9.8 for anti-CCP positivity alone to 13.8 for dual antibody positivity, creating a powerful rule-in diagnostic approach .
-
Either antibody positive ("anti-CCP OR RF"): This approach yields a pooled sensitivity of 78% (range 52-90%) with specificity of 82% (range 79-96%). While the specificity decreases compared to anti-CCP alone (82% vs. 94%), this strategy reduces false negatives and improves early detection .
The diagnostic odds ratio (DOR) for the "both positive" approach is 33.02, demonstrating strong discriminatory power. False positives with dual antibody positivity are substantially lower (around 4%) than with either marker alone .
What methodological considerations are important when developing and validating anti-CCP antibody assays?
Researchers developing and validating anti-CCP assays should consider:
-
Cutpoint determination: Establish cutpoint factors in both the presence and absence of the target antigen (e.g., 0.779 and 1.282 respectively with 50 ng/ml CP-870,893) .
-
Concentration-response linearity: Determine the linear range of the concentration-response curve (e.g., 1-100 ng/ml for some antibody assays) .
-
Precision validation: Ensure intra- and inter-assay precision with coefficient of variation (CV) ≤ 25% .
-
Specificity and recovery testing: Validate within ±25% of expected values .
-
Sensitivity thresholds: Establish minimum detection limits (e.g., ~500 ng anti-idiotype Mab per ml serum) .
-
Ruggedness testing: Verify technician-to-technician reproducibility (CV ≤ 25%) .
-
Stability assessment: Test stability of positive controls, labeling reagents, and cell lines .
-
Culture media effects: Be aware that assay robustness can be altered by culture media and FBS substitutions .
What are the key considerations when designing clinical studies to evaluate anti-CCP as a prognostic marker?
When designing studies to assess the prognostic value of anti-CCP antibodies:
-
Longitudinal design: Implement prospective cohort studies with adequate follow-up (minimum 2-5 years) to assess progression to erosive disease .
-
Stratification by antibody levels: Analyze outcomes based on antibody titer categories (negative, weak, moderate, strong positive) rather than binary positive/negative results .
-
Combined biomarker assessment: Include both anti-CCP and RF testing, along with other inflammatory markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) .
-
Radiographic outcome measures: Use standardized scoring systems for radiographic progression to ensure comparable results across studies .
-
Disease activity correlation: Assess correlation between anti-CCP levels and disease activity scores (DAS). Studies have demonstrated statistically significant correlations between anti-CCP antibodies and DAS (r=0.437), with the highest levels of anti-CCP antibodies (>80 UI/ml) found in patients with intensely active RA (DAS>5.1) .
How can researchers address the heterogeneity in anti-CCP testing methodology across studies?
To address methodological heterogeneity:
What emerging technologies might improve anti-CCP antibody detection sensitivity and specificity?
Emerging approaches for enhancing anti-CCP testing include:
-
Multiplexed assays: Development of platforms that simultaneously test for multiple autoantibodies, including different anti-citrullinated protein antibodies (ACPAs).
-
IgA anti-CCP detection: Incorporation of IgA in addition to IgG antibodies against CCP enhances sensitivity for RA diagnosis. Some RA patients have IgA antibodies to CCP in the absence of IgG, making combined detection valuable .
-
Novel biomarker combinations: Investigation of anti-CCP antibodies in combination with other biomarkers beyond RF to improve diagnostic accuracy.
-
Next-generation assays: Development of fourth-generation CCP assays with improved epitope selection for enhanced sensitivity while maintaining high specificity .
How can researchers evaluate the impact of anti-CCP testing on treatment decisions and outcomes?
To assess the clinical impact of anti-CCP testing on therapeutic decisions:
-
Treatment-stratified trials: Design studies where treatment decisions are partly based on anti-CCP status to evaluate whether antibody-guided therapy improves outcomes.
-
Precision medicine approaches: Investigate whether patients with different anti-CCP profiles respond differently to specific disease-modifying antirheumatic drugs (DMARDs) or biologics.
-
Economic analyses: Conduct cost-effectiveness studies to determine the value of routine anti-CCP testing in guiding treatment decisions. Current evidence suggests anti-CCP testing may be cost-effective due to its high specificity and prognostic value .
-
Guideline implementation research: Evaluate the impact of incorporating anti-CCP testing into clinical practice guidelines on early diagnosis rates and disease outcomes.
What sample handling and storage protocols optimize anti-CCP antibody detection in research settings?
Optimal sample handling protocols include:
-
Collection: Use serum separator tubes (SST) for blood collection .
-
Processing timeframe: Separate serum from cells as soon as possible or within 2 hours of collection .
-
Transfer requirements: Transfer 1.0 mL of serum to a standard transport tube (minimum 0.5 mL) .
-
Storage conditions and durations:
-
Sample exclusion criteria: Reject contaminated, heat-inactivated, grossly hemolyzed, grossly icteric, or grossly lipemic specimens .
How can researchers develop custom anti-CCP antibodies for specialized experimental applications?
For custom antibody development targeting citrullinated peptides:
-
Antigen design: Select and design target antigens (proteins or peptides) that contain citrullinated epitopes. Use bioinformatics tools like homology modeling to identify accessible epitopes and analyze protein structures/sequences to pinpoint regions for antibody development .
-
Immunization strategies: Develop protocols for generating immune responses against citrullinated peptides in host animals .
-
Hybridoma generation: For monoclonal antibody production, create hybridomas by fusing antibody-producing B cells with myeloma cells .
-
Recombinant display technologies: Alternative approaches include phage display or other recombinant technologies to generate antibodies with desired specificity .
-
Antibody production and purification: Establish protocols for large-scale production and purification of the custom antibodies .
-
Characterization: Thoroughly characterize antibodies for specificity, sensitivity, and cross-reactivity to ensure they recognize only citrullinated epitopes .
